Yang Deok-Hwan, Lee Je-Jung, Mun Yeung-Chul, Shin Ho-Jin, Kim Yeo-Kyeoung, Cho Sang-Hee, Chung Ik-Joo, Seong Chu-Myong, Kim Hyeoung-Joon
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea.
Am J Hematol. 2007 Jan;82(1):1-5. doi: 10.1002/ajh.20739.
CD56 expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia and multidrug resistance, but its clinical and prognostic significance has not been clearly identified. This study examined CD56 expression in 37 adult de novo AML patients with t(8:21). CD56 was expressed in 25 cases (67.6%). Complete remission (CR) rates were similar in both groups (91.7% vs. 88.7%; P = 0.73), but the relapse rates differed considerably (60% vs. 25%; P = 0.02). The median duration of disease-free survival (DFS) was significantly shorter in the CD56+ (median, 12.2 +/- 6.4 months) than in the CD56- group (median, not reached) (P = 0.02). In addition, the median duration of survival differed significantly in the CD56+ group (median, 14.9 +/- 4.4 months) compared with the CD56- group (median, not reached) (P = 0.01). Of the fifteen transplanted patients who achieved CR, allogeneic HST was performed from their siblings. The median duration of DFS in the CD56+ patients was significantly shorter than the CD56- patients (median, 24.4 +/- 4.5 months vs. median, not reached; P = 0.02). We concluded that CD56 expression correlates to a reduced DFS and survival for AML patients with t(8:21), including those patients who underwent transplantation.
急性髓系白血病（AML）中CD56的表达与髓外白血病及多药耐药相关，但其临床及预后意义尚未明确。本研究检测了37例成人初发t(8;21) AML患者的CD56表达情况。25例（67.6%）患者表达CD56。两组的完全缓解（CR）率相似（91.7%对88..7%；P = 0.73），但复发率差异显著（60%对25%；P = 0.02）。CD56阳性组的无病生存期（DFS）中位数显著短于CD56阴性组（中位数为12.2±6.4个月对未达到；P = 0.02）。此外，CD56阳性组的生存期中位数与CD56阴性组相比差异显著（中位数为14.9±4.4个月对未达到；P = 0.01）。在15例达到CR的移植患者中，均接受了来自其同胞的异基因造血干细胞移植。CD56阳性患者的DFS中位数显著短于CD56阴性患者（中位数为24.4±4.5个月对未达到；P = 0.02）。我们得出结论，CD56表达与t(8;21) AML患者，包括接受移植的患者的DFS降低及生存期缩短相关。
